Literature DB >> 15731489

Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study.

Angel Brea1, Daniel Mosquera, Eva Martín, Ana Arizti, José L Cordero, Emilio Ros.   

Abstract

OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) frequently coexists with obesity, diabetes, and dyslipidemia. We examined whether NAFLD was associated with atherosclerosis, as measured by ultrasound in the carotid arteries. METHODS AND
RESULTS: Carotid atherosclerosis and cardiovascular risk factors were assessed in 40 patients with an ultrasound diagnosis of primary NAFLD and 40 matched population controls. The metabolic syndrome and all its individual traits, including elevated C-reactive protein, were significantly (P<0.005) more frequent in NAFLD patients than in control subjects. Patients with NAFLD showed more carotid atherosclerosis than controls, with mean intima-media thickness (IMT) of 0.70+/-0.20 mm and 0.54+/-0.13 mm (P<0.0001) and plaque prevalence of 50% and 25% (P=0.021), respectively. By multivariate analysis, older age (odds ratio [OR], 2.5 per 10 years; 95% CI, 1.4 to 4.4; P=0.002), the presence of NAFLD (OR, 8.4; 95% CI, 2.49 to 29.4; P=0.001), and elevated serum ferritin (OR, 3.1; 95% CI, 1.2 to 7.9; P=0.016) were independent predictors of an increased IMT.
CONCLUSIONS: Patients with NAFLD show a cluster of risk factors of the metabolic syndrome and advanced carotid atherosclerosis. NAFLD appears to be a feature of the metabolic syndrome, and its detection on abdominal ultrasound should alert to the existence of an increased cardiovascular risk.

Entities:  

Mesh:

Year:  2005        PMID: 15731489     DOI: 10.1161/01.ATV.0000160613.57985.18

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  110 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

2.  Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine.

Authors:  Elango Kathirvel; Kengathevy Morgan; Ganesh Nandgiri; Brian C Sandoval; Marie A Caudill; Teodoro Bottiglieri; Samuel W French; Timothy R Morgan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-08-19       Impact factor: 4.052

3.  Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis.

Authors:  Jia Cai; Shujun Zhang; Wenxiang Huang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  Preclinical cardiac disease in nonalcoholic fatty liver disease with and without metabolic syndrome.

Authors:  Jasbir Makker; Hassan Tariq; Jonathan N Bella; Kishore Kumar; Chukwunonso Chime; Harish Patel; Muhammad Umar Kamal; Danial Shaikh; Vamshidhar Vootla; Bharat Bajantri; Umut Gomceli; Mohammad Alshelleh; Richard Peralta; Aiyi Zhang; Sridhar Chilimuri
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

5.  Nonalcoholic fatty liver disease is associated with coronary artery calcification.

Authors:  Donghee Kim; Su-Yeon Choi; Eun Ha Park; Whal Lee; Jin Hwa Kang; Won Kim; Yoon Jun Kim; Jung-Hwan Yoon; Sook Hyang Jeong; Dong Ho Lee; Hyo-suk Lee; Joseph Larson; Terry M Therneau; W Ray Kim
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

6.  Npc1 haploinsufficiency promotes weight gain and metabolic features associated with insulin resistance.

Authors:  David Jelinek; Veronica Millward; Amandip Birdi; Theodore P Trouard; Randall A Heidenreich; William S Garver
Journal:  Hum Mol Genet       Date:  2010-10-29       Impact factor: 6.150

7.  Dioxin-like PCB 126 Increases Systemic Inflammation and Accelerates Atherosclerosis in Lean LDL Receptor-Deficient Mice.

Authors:  Michael C Petriello; J Anthony Brandon; Jessie Hoffman; Chunyan Wang; Himi Tripathi; Ahmed Abdel-Latif; Xiang Ye; Xiangan Li; Liping Yang; Eun Lee; Sony Soman; Jazmyne Barney; Banrida Wahlang; Bernhard Hennig; Andrew J Morris
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

8.  Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study.

Authors:  Ryan L McKimmie; Kurt R Daniel; J Jeffrey Carr; Donald W Bowden; Barry I Freedman; Thomas C Register; Fang-Chi Hsu; Kurt K Lohman; Richard B Weinberg; Lynne E Wagenknecht
Journal:  Am J Gastroenterol       Date:  2008-10-03       Impact factor: 10.864

9.  The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.

Authors:  Naim Alkhouri; Tarek Abu-Rajab Tamimi; Lisa Yerian; Rocio Lopez; Nizar N Zein; Ariel E Feldstein
Journal:  Dig Dis Sci       Date:  2009-12-05       Impact factor: 3.199

10.  Levels of soluble CD40 ligand and P-Selectin in nonalcoholic fatty liver disease.

Authors:  Cemal Nuri Ercin; Teoman Dogru; Serkan Tapan; Yildirim Karslioglu; Cem Haymana; Selim Kilic; Alper Sonmez; Zeki Yesilova; Ahmet Uygun; Mustafa Gulsen; Sait Bagci; M Kemal Erbil
Journal:  Dig Dis Sci       Date:  2009-05-14       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.